TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31133629
Drug: Drug consumption
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug consumption for MSP
Study: 28219458
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy - Cognitive Only (CPT)
Study: 15565613
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 units subcutaneously weekly)
Study: 12171679
Drug: SPF 15
Normalized name: Carmex Original SPF 15
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) applied 30 minutes before UVA irradiation.
Study: 12171679
Drug: SPF 15
Normalized name: Carmex Original SPF 15
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) with additional pretreatment using AGR-containing vehicle (Eucerin Gel Cream Phase 1) twice daily for 3 and 7 days.
Study: 12171679
Drug: Pre-sun preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-sun preparation applied twice daily for 1 week before vacation and SPF 15 sunscreen used 30 minutes before sun exposure.
Study: 12171679
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for acne aestivalis patients.
Study: 7848005
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg daily for 10 days)
Study: 7848005
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg every two days)
Study: 7848005
Drug: Erythromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (30 g)
Study: 3288075
Drug: Elevated intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated intranasal temperature (inhalation of saturated hot air at 42-44 degrees C)
Study: 30426269
Drug: Contact points
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact points of the implant with femoral cortical bone
Study: 27545871
Drug: 25% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% SLS formulation
Study: 27545871
Drug: 12.5% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% SLS formulation
Study: 27545871
Drug: 3% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% SLS formulation
Study: 27545871
Drug: Reference 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference 50% SLS formulation
Study: 27545871
Drug: Alectinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (600 mg)
Study: 20836913
Drug: Annual medication
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual medication assessment as part of a Comprehensive Geriatric Assessment (CGA) by physicians (n = 361)
Study: 18323492
Drug: Comparison therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison therapy
Study: 10973767
Drug: Eptifibatide (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (180 microg/kg bolus followed by continuous infusion of 0.75 microg/kg/min for 72 hours)
Study: 1501118
Drug: Diphenhydramine (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (100, 200 and 400 mg)
Study: 1501118
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 and 4 mg)
Study: 1501118
Drug: Methocarbamol (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methocarbamol (2.25 and 9 g)
Study: 30850411
Drug: Ulinastatin (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (intravenously administered every 8 hours for a total of 600,000 U/day for five consecutive days)
Study: 29174695
Drug: Inactivated oral
Normalized name: typhoid vaccine, inactivated oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated oral cholera vaccine (OCV)
Study: 25076161
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily for 2 days before PET/CT scan
Study: 16773037
Drug: Sustained-release fampridine
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release fampridine 25 mg b.i.d. (Group I)
Study: 16773037
Drug: Sustained-release fampridine
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release fampridine 40 mg b.i.d. (Group II)
Study: 12236050
Drug: Vaginal capsule
Normalized name: VAGINAL CAPSULE, HARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal capsule containing 200 mg progesterone
Study: 12236050
Drug: Vaginal gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel containing 90 mg progesterone
Study: 9822445
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose load during intermediate NaCl diet
Study: 9822445
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose load after each diet
Study: 2912427
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug therapy with lovastatin and colestipol
Study: 1098542
Drug: Classical cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical cholera vaccine with yellow fever vaccine
Study: 1098542
Drug: Purified fraction
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified fraction vaccine with yellow fever vaccine
Study: 1098542
Drug: Classical cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical cholera vaccine
Study: 1098542
Drug: Purified fraction
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified fraction vaccine
Study: 28327122
Drug: Midodrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (20 mg) three times a day
Study: 27885221
Drug: Trial Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial Gel B
Study: 22995879
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy with contemporary antithrombin regimens (bivalirudin or heparin plus glycoprotein IIb/IIIa inhibitor)
Study: 18093307
Drug: Sudarshan Kriya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sudarshan Kriya and related practices (SK&P) - practiced daily for six weeks
Study: 7982184
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release metoclopramide (CRM) 40 mg every 12 hours for 3 days
Study: 7982184
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release metoclopramide (IRM) 20 mg every 6 hours for 3 days
Study: 25545629
Drug: rasagiline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 2 mg/day
Study: 23642947
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of Lf/IgF daily for 90 days
Study: 20605427
Drug: Pudding with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudding with 10 g oat bran DF
Study: 20605427
Drug: Pudding with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudding with 10 g wheat bran DF
Study: 20605427
Drug: Pudding with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudding with 5 g wheat bran DF + 5 g oat bran DF
Study: 1572248
Drug: Captopril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (2.5 or 5.0 mg slow intravenous bolus followed by continuous infusion of 1.5‐2.0 mg/h for 48 hours)
Study: 1572248
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same mode of administration as captopril)
Study: 21982313
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy-defibrillator (CRT-D)
Study: 18507661
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin plus 1 mg glucagon
Study: 18507661
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin alone (placebo)
Study: 7561530
Drug: Anti-TB chemotherapy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB chemotherapy with rifampicin (isoniazid, pyrazinamide, ethambutol, and rifampicin)
Study: 7561530
Drug: Anti-TB chemotherapy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB chemotherapy without rifampicin (isoniazid, pyrazinamide, and ethambutol)
Study: 7561530
Drug: Anti-TB chemotherapy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB chemotherapy with rifampicin
Study: 7561530
Drug: Anti-TB chemotherapy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB chemotherapy without rifampicin
Study: 1766577
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of reduced GSH for 30 days
Study: 1766577
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of vitamin K for 30 days
Study: 7184670
Drug: Chlorpropamide tablet
Normalized name: Chlorpropamide Tablets
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpropamide tablet (250 mg)
Study: 760732
Drug: Chlorpropamide suspension
Normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpropamide suspension
Study: 19678780
Drug: C. domestica
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. domestica extracts 2 g per day for 6 weeks
Study: 19678780
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg per day for 6 weeks
Study: 15895286
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1 mg/day p.o. for 3 months
Study: 12572869
Drug: Germinated barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germinated barley foodstuff (GBF) 20-30 g daily for 4 weeks
Study: 12572869
Drug: Baseline anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline anti-inflammatory therapy for 4 weeks
Study: 9734472
Drug: Arachidonic acid
Normalized name: Arachidonic acid
DrugBank: Arachidonic Acid (DB04557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arachidonic acid (AA) at doses of 10(-10) to 10(-5) mol/L
Study: 9734472
Drug: 17-octadecynoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-octadecynoic acid (17-ODYA) at 10(-5) mol/L (P450 inhibitor)
Study: 9734472
Drug: Indomethacin (INDO)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (INDO) at 10(-5) mol/L (cyclooxygenase inhibitor)
Study: 9734472
Drug: N omega-nitro-L-arginine
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N omega-nitro-L-arginine methyl ester (L-NAME) at 10(-4) mol/L (NO synthase inhibitor)
Study: 9734472
Drug: Miconazole at
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole at 10(-5) mol/L (P450 inhibitor)
Study: 9734472
Drug: 40 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mmol/L KCl
Study: 9734472
Drug: Charybdotoxin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charybdotoxin at 10(-8) mol/L (large-conductance Ca2+-activated K+ channel blocker)
Study: 1894852
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg bite-and-swallow) after calcium infusion (10 ml of 10% calcium chloride in 50 ml of 5% dextrose in water)
Study: 1894852
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg bite-and-swallow) after placebo infusion (5% dextrose in water)
Study: 1894852
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion (10 ml of 10% calcium chloride in 50 ml of 5% dextrose in water)
Study: 1894852
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (5% dextrose in water)
Study: 1894852
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg bite-and-swallow) after calcium infusion
Study: 30714984
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation therapy (VRT) (n = 20)
Study: 30714984
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of corticosteroids and vestibular rehabilitation (n = 20)
Study: 24427649
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg IV at induction of anesthesia)
Study: 21635675
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg prednisone
Study: 14605050
Drug: Linezolid, 600
Normalized name: Linezolid, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid, 600 mg, q12h for 7 to 21 days
Study: 14605050
Drug: Vancomycin, 1
Normalized name: Vancomycin, 100 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin, 1 g, q12h for 7 to 21 days
Study: 8632551
Drug: Self-injection
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-injection
Study: 30312159
Drug: Manualized Swedish
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manualized Swedish massage therapy (SMT)
Study: 22196125
Drug: Early aquatic
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early aquatic therapy (after 6 days)
Study: 22196125
Drug: Late aquatic
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late aquatic therapy (after 14 days)
Study: 21048810
Drug: Silymarin and
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin and selenium (SM-Se) combination (570 mg of silymarin and 240 µg of selenium as selenomethionine)
Study: 16955461
Drug: HCV antibody
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV antibody detection immunoassay
Study: 9821996
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide administered to patients receiving norepinephrine
Study: 9821996
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide administered to patients not receiving norepinephrine
Study: 9051541
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg (Group MH)
Study: 9051541
Drug: Midazolam 0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.035 mg/kg (Group ML)
Study: 1276560
Drug: Medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine group (antidepressive drug treatment)
Study: 1276560
Drug: Natural Process
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Process group (no treatment)
Study: 21421014
Drug: GLP‐2, 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐2, 1600 μg subcutaneously (SC)
Study: 19333166
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg, 3 times daily)
Study: 19333166
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet, 3 times daily)
Study: 16943675
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with standardized latex extract
Study: 9230243
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice daily for 6 months
Study: 3318371
Drug: DPI 201-106
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI 201-106 (80 mg and 100 mg)
Study: 20386077
Drug: darunavir/ritonavir 900/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 900/100 mg once daily
Study: 20386077
Drug: darunavir/ritonavir 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 600/100 mg twice daily
Study: 7569093
Drug: Iopentol 300
Normalized name: iopentol 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol 300 mg/ml
Study: 7569093
Drug: Iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 300 mg/ml
Study: 28505367
Drug: Health Information
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Information Exchange (HIE) access during medication reconciliation
Study: 26271132
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (basic medication without acupuncture intervention).
Study: 16826094
Drug: Ceramic-on-ceramic (Ce/Ce)
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramic-on-ceramic (Ce/Ce) implant
Study: 16826094
Drug: Metal-on-polyethylene (PE)
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal-on-polyethylene (PE) implant
Study: 14616428
Drug: Diltiazem co-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem co-treatment (30 mg or 60 mg twice daily depending on weight)
Study: 11097144
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice pretreatment with oral scopolamine 0.5 mg
Study: 11097144
Drug: Intravenous scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous scopolamine 0.5 mg
Study: 11097144
Drug: Scopolamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine administration (all routes)
Study: 9505992
Drug: Microemulsion oral
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion oral solution
Study: 9505992
Drug: Microemulsion soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion soft gelatin capsule
Study: 9505992
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral solution
Study: 9505992
Drug: Microemulsion capsule
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion capsule (200, 400, 600 mg)
Study: 9505992
Drug: Microemulsion capsule
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion capsule (400 mg after a fat-rich meal)
Study: 9505992
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose levels of microemulsion formulation
Study: 30824635
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab (GOL) 2 mg/kg
Study: 26597577
Drug: Ice pack
Normalized name: Ice Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice pack therapy for 24 hours after surgery
Study: 22775354
Drug: Gabapentin-ER 600
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin-ER 600 mg evening (pm)
Study: 22775354
Drug: Gabapentin-ER 600
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin-ER 600 mg morning (am)/600 mg pm
Study: 22775354
Drug: Gabapentin-ER 1200
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin-ER 1200 mg pm
Study: 22775354
Drug: Gabapentin-ER 600
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin-ER 600 mg am/1200 mg pm
Study: 22775354
Drug: Gabapentin-ER 600
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin-ER 600 mg am/1800 mg pm
Study: 22775354
Drug: Gabapentin-ER 1200
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin-ER 1200 mg am/1800 mg pm
Study: 22775354
Drug: Gabapentin-ER (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin-ER (all doses)
Study: 16352299
Drug: Tiropramide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiropramide (100 mg dose)
Study: 16352299
Drug: Control formulation
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulation of Tiropramide (100 mg dose)
Study: 15257956
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) treatment
Study: 11565838
Drug: IL-2 (125,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (125,000 IU/kg subcutaneously daily for 12 days)
Study: 28414254
Drug: Pressure Ulcer
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pressure Ulcer Prevention Program (lifestyle-based treatment administered by healthcare professionals, largely via in-home visits and phone contacts)
Study: 27258530
Drug: Modified Beck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Beck Depression Inventory (BDI)-II administered to adults randomly selected from the community (n=221)
Study: 12841925
Drug: 0.05% azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% azelastine eye drops, twice daily for 6 weeks
Study: 12841925
Drug: Open-label levocabastine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label levocabastine, twice daily for 6 weeks
Study: 10989958
Drug: Endothelin-1 (ET-1)
Normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 (ET-1) infusion at 20 ng/min x kg
Study: 10989958
Drug: Endothelin-3 (ET-3)
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-3 (ET-3) infusion
Study: 9149659
Drug: Trans-fatty acids
Normalized name: Patty Cake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-fatty acids (top quintile intake, median = 6.2 g/day)